Supplemental Content: Living Well with Migraine Disease and Headaches

Keep up with Migraine & headache news, tips, tools, and more... View our blog!


 

Triptans Pose Less Risk Than OTC Meds for Some Patients

Report demonstrates triptans safer than NSAIDs for some patients

Since triptans (Imitrex/sumatriptan, Maxalt/rizatriptan, etc.) were introduced in 1992, some doctors have been reluctant to prescribe them because of concerns about cardiovascular safety. Some refused to prescribe them for patients beyond a certain age even if they had no history of or risk factors for coronary artery disease.

The Triptan Cardiovascular Safety Expert Panel¹ of the American Headache Society (AHS), after reviewing dozens of studies and adverse event reports on triptans from the US Food and Drug Administration's Adverse Event Reporting System, has come to a conclusion vital to those who suffer from Migraines and cluster headaches.

Referring to patients who have no risks of cardiovascular disease, Dr. David Dodick commented,

    "While serious cardiovascular events have been reported after the use of triptans, their occurrence appears to be extremely low -- on the order of less than one in 1 million."²

Such figures put triptans in a better safety position than over-the-counter non-steroidal anti-inflammatory medications (NSAID's) such as ibuprofen, acetaminophen, and aspirin. The risk of death from those medications is as little as one in 1,200, while prescription NSAID's contribute to approximately 16,500 deaths per year.³

The panel's findings add to a growing body of evidence of the safety of triptans. Two recent studies analyzed more than 194,000 Migraine patients in the United States and United Kingdom, and when comparing them to non-Migraine sufferers, found no evidence of increased risk of heart attacks, stroke or death in those who used triptans. In addition, the FDA presented information suggesting that the risk of a person experiencing a heart attack or sudden cardiac death was less than 1 for 10 million patients treated per year, and less than 10 per 10 million Migraine attacks treated per year. Essentially, the risk of these events for patients taking triptans is the same as the risk of these events occurring in the general population.³

Dr. Stephen Silberstein, director of the Jefferson Headache Center in Philadelphia, agreed with the findings, saying, "There's good evidence that triptans are far superior in fighting Migraine than whatever else is out there ... It usually takes doctors about 10 years to prescribe any new drugs because they weren't taught about them in medical school."²

The Conclusions of the Panel"

  • Chest symptoms occurring during use of triptans are usually nonserious and usually not attributed to ischemia (deficiency of blood flow).
  • While serious cardiovascular adverse events have occurred after use of triptans, their incidence in clinical trials and clinical practice appears to be extremely low.
  • The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.
  • Most clinical trials and clinical practice data on triptans are derived from patients without known coronary artery disease.
  • These data support the conclusion that, in patients at low risk of coronary artery disease, triptans can be prescribed confidently without the need for prior cardiac status evaluation.¹

"We hope this study enables physicians to make informed decisions when prescribing medications for their patients with Migraines," said Robert B. Daroff, M.D., president of the American Headache Society. "There's no reason for those who get Migraine to suffer when there is an effective remedy available that is safe for the overwhelming majority of Migraine sufferers."³

Dr. Fred Sheftell -- founder and directory of the New England Center for Headache, Medical Advisor Chair for MAGNUM, President-Elect of the American Council for Headache Education (ACHE), and Past Chairman of the World Headache Alliance (WHA) -- commented:

    "The data from the Triptan Cardiovascular Safety Expert Panel gives us a thoughtful and scientific review of safety issues related to a class of medication that in my experience represents the most significant advance in the treatment of the acute attack of migraine in the past one hundred years. It is important to recognize that no triptan should be regarded as 'safer' than another. Indeed all provide a margin of safety that should give clinicians and patients alike comfort in their use.

    Nevertheless, one must still pay attention to the contraindications for the class."4

Take Note:

  • One out of ten people have Migraine disease.
  • 90% of Migraineurs report some disability cause by their attacks according to the American Migraine Study II.
  • The World Health Organization ranks Migraine among the world's most disabling illnesses.
  • Triptans are effective for approximately 80% of Migraineurs, BUT
  • Triptans are prescribed for only approximately 30% of Migraineurs, SO
  • Many Migraineurs haven't had the opportunity to try triptans.

Thus, just a bit beyond the ten-year mark Dr. Silberstein mentioned, the Panel gives us safety information about triptans that will hopefully benefit millions of sufferers. While those Migraineurs who have coronary and other contraindications still should not take triptans, those who don't have those contraindications and their doctors should now be far more comfortable in taking advantage of the benefits triptans can offer.

___________
References:

¹ Dodick, David, Lipton, Richard B., Martin, Vincent, Papademetriou, Vasilios, Rosamond, Wayne, MaassenVanDenBrink, Antoinette, Loutfi, Hassan, Welch, K. Michael, Goadsby, Peter J., Hahn, Steven, Hutchinson, Susan, Matchar, David, Silberstein, Stephen, Smith, Timothy R., Purdy, R. Allan & Saiers, Jane (2004). Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain 44 (5), 414-425. doi: 10.1111/j.1526-4610.2004.04078.x

² Mundell, E.J.; HealthDay Reporter. "Migraine Sufferers Not Getting Best Drugs." Forbes.com. May 5, 2004.

³ U.S. Newswire Press Release. "Triptans Safer Than Many Common Drugs; Underused Treatment Most Effective Migraine Medication." May 5, 2004.

4 Interview with Dr. Fred Sheftell by Teri Robert. May 8, 2004.

Originally published May 10, 2004.
© Teri Robert

 

 
Tell a friend about this article:
 
NOTE: The information on this site is for education and support only. It is not medical advice and should not be construed as such. Always consult your physician if you have new or different symptoms. Never change your treatment regimen or add herbals, supplements, etc., without consulting your doctor.

 The American Headache and Migraine Association (AHMA)...

a patient-focused, patient-driven organization for patients with Migraine and
other headache disorders and their family, friends, and care partners.
Anyone interested in the concerns or patients with these disorders is welcome to join.

The AHMA exists to EASE the burden of Migraine and other headache disorders through Education, Awareness, Support, and Engagement.

www.ahma.ws


 

This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information: verify here.
    

Search only trustworthy HONcode health websites:

NOTE: The information on this site is for education and support only. It is not medical advice and should not be construed as such. Always consult your physician if you have new or different symptoms. Never change your treatment regimen or add herbals, supplements, etc., without consulting your doctor.

All content on this site is physician reviewed by Dr. John Claude Krusz.

Our Mission & Purpose  •   About the Information on This Site  •   Our Privacy Policy  •   Site Funding, Advertising, & Linking  •   Contact

All content © 2004 - 2014, Teri Robert unless otherwise indicated. • All rights reserved.
Last updated Saturday, September 27, 2014.

Page copy protected against web site content infringement by Copyscape

 
     
 
advertisement  

Looking for awareness items? Your search is over...

"Headaches Do Not Have Me" Mug

from Cafe Press

"Not the Boss" Thermos Tea Tumbler

from Cafe Press

"Knowledge Is Power"
Tile Box

from Cafe Press

"Migraines Are Not the Boss of Me!"

from Cafe Press

 

You can find these and other items in our Awareness Shop!

advertisement

advertisement

Google
  Web www.helpforheadaches.com